Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can pre existing liver issues increase tigecycline's liver enzyme changes?Lipitor blood pressure?What are vascepa's co pay assistance options?Is vivitrol covered by most insurance plans?Should lipitor dosage be adjusted with beef meals?
See the DrugPatentWatch profile for ruxolitinib
What is the current status of Apotex’s ruxolitinib generic in the US? Apotex has filed an Abbreviated New Drug Application (ANDA) for a generic version of Jakafi (ruxolitinib phosphate) with the FDA, but the application remains under review and no approval has been granted. Why has the FDA not approved Apotex’s generic yet? The delay stems mainly from ongoing patent litigation. Incyte and Novartis, the innovators, have asserted multiple patents covering the composition, use, and formulation of ruxolitinib. Apotex’s filing triggered a 30-month stay under the Hatch-Waxman Act, and that stay has not yet expired for all listed patents. When do the patents protecting Jakafi expire? Key U.S. patents covering ruxolitinib are scheduled to expire between 2026 and 2030, with some extensions possible through pediatric exclusivity or other adjustments. [1] What happens if Apotex wins or settles the patent case? If Apotex obtains a favorable court ruling or reaches a settlement allowing earlier entry, the generic could launch at risk or under a license once the 30-month stay lifts. Conversely, an unfavorable ruling would push launch to the date of the last-to-expire patent or later. Are other companies also seeking generic ruxolitinib? Yes. Several firms, including Teva, Sun Pharma, and Hetero, have also filed ANDAs for ruxolitinib. Multiple Paragraph IV challenges increase the likelihood of eventual generic competition, but each filer must still clear the same patent hurdles. How does the regulatory path differ for biosimilars versus this small-molecule generic? Ruxolitinib is a small-molecule drug, so Apotex is following the standard ANDA pathway with bioequivalence data. Biosimilars, in contrast, require more extensive analytical and clinical studies under the Biologics Price Competition and Innovation Act, a route not applicable here. [1] DrugPatentWatch.com – Ruxolitinib patents and expiration dates: https://www.drugpatentwatch.com
Other Questions About Ruxolitinib :